PMID- 22150123
OWN - NLM
STAT- MEDLINE
DCOM- 20120927
LR  - 20211203
IS  - 1365-2362 (Electronic)
IS  - 0014-2972 (Linking)
VI  - 42
IP  - 6
DP  - 2012 Jun
TI  - Inorganic phosphate and FGF-23 predict outcome in stable systolic heart failure.
PG  - 649-56
LID - 10.1111/j.1365-2362.2011.02631.x [doi]
AB  - BACKGROUND: Recent studies show associations between inorganic phosphate and risk 
      of heart failure in the general population as well as between fibroblast growth 
      factor 23 (FGF-23) and outcome in coronary heart disease. This study was carried 
      out to assess whether circulating levels of inorganic phosphate and FGF-23, a new 
      central hormone in mineral bone metabolism, predict outcome in systolic heart 
      failure. MATERIALS AND METHODS: Ninety-nine consecutive outpatients with systolic 
      heart failure were enrolled. Mean (SD) age was 61 years (11), mean left 
      ventricular ejection fraction (LVEF) was 33% (10), 82 patients were men, median 
      estimated creatinine clearance was 83 mL/min (Q(1) -Q(3) 58-106), median NTproBNP 
      level was 803 pg/mL (Q(1) -Q(3) 404-2757), median inorganic phosphate was 1.12 mM 
      (Q(1) -Q(3) 1.02-1.22), median FGF-23 was 39.02 pg/mL (Q(1) -Q(3) 32.45-55.86) 
      and median follow-up was 35 months. Associations between inorganic phosphate, 
      FGF-23 and endpoints were assessed using Cox regression analyses. RESULTS: 
      Inorganic phosphate and FGF-23 levels were significantly higher (P < 0.001 and P 
      = 0.009) in patients reaching the combined endpoint of cardiac hospitalization or 
      death. FGF-23 (ln) predicted all-cause mortality (hazard ratio (HR) 5.042, P = 
      0.032) in a model adjusted for age, gender, estimated creatinine clearance, LVEF, 
      New York Heart Association (NYHA) stage and NTproBNP level. Inorganic phosphate 
      predicted heart failure hospitalization (HR 26.944, P = 0.021), cardiac 
      hospitalization (HR 16.016, P = 0.017) and the combined endpoint (HR 13.294, P = 
      0.015) in models adjusted for the same co-variables. CONCLUSION: The results of 
      this study demonstrate the independent prognostic value of inorganic phosphate 
      and FGF-23 in heart failure even in the context of established risk markers.
CI  - (c) 2011 The Authors. European Journal of Clinical Investigation (c) 2011 Stichting 
      European Society for Clinical Investigation Journal Foundation.
FAU - Plischke, Max
AU  - Plischke M
AD  - Division of Nephrology and Dialysis, Department of Internal Medicine III, Medical 
      University of Vienna, Vienna, Austria.
FAU - Neuhold, Stephanie
AU  - Neuhold S
FAU - Adlbrecht, Christopher
AU  - Adlbrecht C
FAU - Bielesz, Bernhard
AU  - Bielesz B
FAU - Shayganfar, Sascha
AU  - Shayganfar S
FAU - Bieglmayer, Christian
AU  - Bieglmayer C
FAU - Szekeres, Thomas
AU  - Szekeres T
FAU - Horl, Walter H
AU  - Horl WH
FAU - Strunk, Guido
AU  - Strunk G
FAU - Vavken, Patrick
AU  - Vavken P
FAU - Pacher, Richard
AU  - Pacher R
FAU - Hulsmann, Martin
AU  - Hulsmann M
LA  - eng
PT  - Journal Article
DEP - 20111213
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
RN  - 0 (FGF23 protein, human)
RN  - 0 (Phosphates)
RN  - 62031-54-3 (Fibroblast Growth Factors)
RN  - 7Q7P4S7RRE (Fibroblast Growth Factor-23)
SB  - IM
MH  - Cohort Studies
MH  - Female
MH  - Fibroblast Growth Factor-23
MH  - Fibroblast Growth Factors/*blood
MH  - Heart Failure, Systolic/*blood/mortality
MH  - Hospitalization
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Phosphates/*blood
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Prospective Studies
MH  - Regression Analysis
MH  - Risk Assessment
MH  - Risk Factors
EDAT- 2011/12/14 06:00
MHDA- 2012/09/28 06:00
CRDT- 2011/12/14 06:00
PHST- 2011/12/14 06:00 [entrez]
PHST- 2011/12/14 06:00 [pubmed]
PHST- 2012/09/28 06:00 [medline]
AID - 10.1111/j.1365-2362.2011.02631.x [doi]
PST - ppublish
SO  - Eur J Clin Invest. 2012 Jun;42(6):649-56. doi: 10.1111/j.1365-2362.2011.02631.x. 
      Epub 2011 Dec 13.